Cat. No.: DAA-001173
Product Information | |
---|---|
Product Name | Mouse IL-1β Antibody Pair - BSA and Azide free |
Species | Mouse |
Description | The Antibody Pair can be used to quantify Mouse IL-1 beta (Interleukin-1 beta). BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/mL as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results. |
Detection Range | 7.8 pg/mL - 500 pg/mL |
Target Information | |
---|---|
Target Name | IL1B |
UniProt No. | P01584 |
Gene ID | 3553 |
Target Description | Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. |
Alternative Names | Catabolin; H1; IFN beta inducing factor; IL 1; IL 1 beta; IL-1 beta; IL1; IL1 BETA; IL1B; IL1B_HUMAN; IL1F2; Interleukin 1 beta; Interleukin 1 beta precursor; interleukin 1, beta; Interleukin-1 beta; OAF; Osteoclast activating factor; OTTHUMP00000162031; Preinterleukin 1 beta; Preinterleukin beta; Pro interleukin 1 beta |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.